What diseases does Vandetanib mainly treat?

Vandetanib is a multi-target tyrosine kinase inhibitor mainly used to treat unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC; thyroid cancer). This type of tumor originates from thyroid C cells and is highly invasive. Traditional radiotherapy and chemotherapy have limited effects. Vandetanib inhibits tumor growth by simultaneously inhibiting multiple signaling pathways, including VEGFR (vascular endothelial growth factor receptor), EGFR (epidermal growth factor receptor) and RET (rearranged oncogene), thereby blocking the proliferation and angiogenesis of tumor cells. Unlike single-target drugs, vandetanib's multi-targeting mechanism enables it to exert a comprehensive inhibitory effect on multiple tumor signaling networks.

Research shows that vandetanib is particularly suitable for patients with medullary thyroid cancer who haveRET mutations, who often respond poorly to traditional drugs. Vandetanib can delay the progression of the disease and control symptoms, such as increased neck mass, hoarseness or difficulty swallowing. It is worth noting that for patients who are asymptomatic or whose disease progresses slowly, the guidelines recommend that treatment should be initiated with caution because vandetanib may cause adverse effects such as abnormal heart rhythm, rash, or diarrhea. Therefore, the use of drugs needs to be decided after the evaluation of a professional doctor to balance the benefits and risks.

Currently, vandetanib has been marketed in the United States, Europe and some Asian countries, and has been included in many thyroid cancer treatment guidelines. Some domestic patients obtain drugs through formal cross-border pharmacies or hospital special drug registration channels. With the in-depth research of targeted therapy in the field of thyroid cancer, vandetanib is regarded as an important option to break through the limitations of traditional treatment, and also provides a new direction for the precision treatment of tumors related to the RET pathway.

Reference materials:https://www.drugs.com/caprelsa.html